SCHEMBL30623756

SCHEMBL30623756

Nc1c(O)c2ccccc2[nH]c1=O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.69
ALDH1A1 P00352 10/20 0.69
MAPT P10636 5/20 0.69
IDE P14735 1/20 0.69
MPI P34949 1/20 0.69
CACNA1B Q00975 1/20 0.69
APBA1 Q02410 1/20 0.69
GRIN2D O15399 2/20 0.59
GRIN3B O60391 2/20 0.59
GRIN1 Q05586 2/20 0.59
GRIN2A Q12879 2/20 0.59
GRIN2B Q13224 2/20 0.59
GRIN2C Q14957 2/20 0.59
GRIN3A Q8TCU5 2/20 0.59
DAO P14920 1/20 0.58
DDO Q99489 1/20 0.58
HPGD P15428 4/20 0.54
HSD17B10 Q99714 4/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9715631 1.00 KDM4E (0.69) KDM4EALDH1A1MAPTIDEMPI
Hydrochloric Acid SCHEMBL11767787 0.98 KDM4E (0.67) KDM4EALDH1A1MAPTIDEMPI
SCHEMBL1884123 0.82 KDM4E (1.00) KDM4EALDH1A1MAPTIDEMPI
SCHEMBL6343134 0.82 KDM4E (0.62) KDM4EALDH1A1MAPTIDEMPI
SCHEMBL8678798 0.78 KDM4E (0.74) KDM4EALDH1A1MAPTIDEMPI
SCHEMBL29505902 0.77 DAO (0.73) KDM4EALDH1A1MAPTIDEMPI
SCHEMBL13847310 0.77 DAO (0.62) KDM4EALDH1A1MAPTIDEMPI
SCHEMBL2726546 0.77 DAO (0.73) KDM4EALDH1A1MAPTIDEMPI
SCHEMBL14969232 0.77 KDM4E (0.69) KDM4EALDH1A1MAPTIDEMPI
SCHEMBL1228041 0.77 KDM4E (0.62) KDM4EALDH1A1MAPTIDEMPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028355-A1 PROTEOLYSIS TARGETING CHIMERA (PROTAC) COMPOSITIONS USING UBIQUITIN CONJUGATING ENZYME LIGANDS BERG, KARA ANN 2026-01-29 US disclosed
CN-119546341-A Proteolytic targeting chimeric (PROTAC) compositions using ubiquitin conjugated enzyme ligands 布普格生物制药公司 2025-02-28 CN disclosed
EP-4429705-A1 PROTEOLYSIS TARGETING CHIMERA (PROTAC) COMPOSITIONS USING UBIQUITIN CONJUGATING ENZYME LIGANDS Berg LLC (US) 2024-09-18 EP disclosed
WO-2023205219-A1 PROTEOLYSIS TARGETING CHIMERA (PROTAC) COMPOSITIONS USING UBIQUITIN CONJUGATING ENZYME LIGANDS BERG LLC (US) 2023-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028355-A1 PROTEOLYSIS TARGETING CHIMERA (PROTAC) COMPOSITIONS USING UBIQUITIN CONJUGATING ENZYME LIGANDS UBE2T, UBE3C, UBE2E1 KDM4E 1637/4885ALDH1A1 3389/4885MAPT 468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.